Posted On: 11/21/2016 11:45:43 AM
Post# of 72446
Here's an example of a company getting bought out after a Phase 2 study.
http://www.fiercebiotech.com/biotech/novartis...Tjg9In0%3D
I don't know how large the market for sickle cell is. But, the point is, deals certainly DO get made after Phase 2.
Quote:
Novartis has exercised its option to buy sickle cell disease player Selexys Pharmaceuticals for up to $665 million . The consummation of the deal follows the publication of Phase II data linking Selexys’ anti-P-selectin antibody to a significant drop in the rate of sickle cell-related pain crises.
http://www.fiercebiotech.com/biotech/novartis...Tjg9In0%3D
I don't know how large the market for sickle cell is. But, the point is, deals certainly DO get made after Phase 2.
(1)
(0)
